EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Diagnostic Accuracy of Anti-factor Xa Activity, PT, and APTT for Clinically Relevant Rivaroxaban Levels in Older AF Patients

Qiang Zhao, Guoquan Chen iD, Haiping Wang, Jiale Chen, Xianqing Hu

Clinical and Applied Thrombosis/Hemostasis · 2026-01 · 32

DOI: 10.1177/10760296261469286 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, online erschienen am 14.07.2026. Verfasst von Qiang Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, China. Hauptthemen laut MEDLINE: Rivaroxaban, Atrial Fibrillation, Factor Xa Inhibitors, Prothrombin Time. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Key Science and Technology Plan Projects of Jinhua, Jinhua Central Hospital Youth Research Foundation, Health Project of Longyan Joint Fund for Scientific and Technological Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rapid assessment of rivaroxaban exposure is clinically critical for older patients with atrial fibrillation in scenarios such as acute bleeding, urgent invasive procedures, or thrombolysis decision-making. This study evaluated rivaroxaban-calibrated anti-factor Xa activity (anti-FXa activity), prothrombin time (PT), and activated partial thromboplastin time (APTT) for identifying clinically relevant rivaroxaban concentrations in older atrial fibrillation patients.

Methods

In this prospective multicenter diagnostic accuracy study, older patients with atrial fibrillation receiving rivaroxaban were enrolled. Liquid chromatography–tandem mass spectrometry (LC-MS/MS) was used as the reference standard, with ≥50 ng/mL defined as the primary diagnostic threshold. Anti-FXa activity, PT, and APTT were evaluated as index tests. Diagnostic performance was assessed using receiver-operating-characteristic analysis, Youden-derived cut-offs, and patient-level clustered bootstrap resampling.

Results

A total of 183 patients were included, contributing 350 LC-MS/MS samples. Anti-FXa activity showed the highest discrimination for identifying LC-MS/MS-measured rivaroxaban concentrations ≥50 ng/mL, with an area under the receiver-operating characteristic curve (AUC) of 0.980 (95% confidence interval [CI], 0.960–0.993), followed by PT (0.904; 95% CI, 0.869–0.938) and APTT (0.825; 95% CI, 0.779–0.869). At Youden-derived cut-offs, anti-FXa activity had sensitivity of 94.0% and specificity of 96.1%, compared with 84.8% and 85.4% for PT, and 74.4% and 81.0% for APTT. Spearman correlations with LC-MS/MS were strongest for anti-FXa activity, followed by PT and APTT.

Conclusion

In this cohort of older patients with AF, anti-factor Xa activity showed the highest diagnostic accuracy for identifying rivaroxaban concentrations ≥50 ng/mL, whereas PT provided moderate discrimination and APTT was less informative.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RivaroxabanAtrial FibrillationFactor Xa InhibitorsProthrombin TimeHumansFemaleMalePartial Thromboplastin TimeAgedProspective StudiesAged, 80 and overTandem Mass Spectrometry

Stichwörter der Autor:innen

LC-MS/MSanti-FXa activityatrial fibrillationdiagnostic accuracyrivaroxaban

Substanzen

RivaroxabanFactor Xa Inhibitors

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, China.
  • Department of Pharmacy, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, China.
  • Department of Pharmacy, Longyan Second Hospital, Longyan, Fujian Province, China.

ORCID-Profile: Guoquan Chen

Förderung

  • the Key Science and Technology Plan Projects of Jinhua
  • Jinhua Central Hospital Youth Research Foundation
  • Health Project of Longyan Joint Fund for Scientific and Technological Innovation

Zitieren

APA

Zhao, Q., Chen, G., Wang, H., Chen, J., & Hu, X. (2026). Diagnostic Accuracy of Anti-factor Xa Activity, PT, and APTT for Clinically Relevant Rivaroxaban Levels in Older AF Patients. Clinical and Applied Thrombosis/Hemostasis, 32. https://doi.org/10.1177/10760296261469286

Vancouver

Zhao Q, Chen G, Wang H, Chen J, Hu X. Diagnostic Accuracy of Anti-factor Xa Activity, PT, and APTT for Clinically Relevant Rivaroxaban Levels in Older AF Patients. Clinical and Applied Thrombosis/Hemostasis. 2026;32. doi:10.1177/10760296261469286

BibTeX
@article{Zhao2026,
  author = {Zhao, Qiang and Chen, Guoquan and Wang, Haiping and Chen, Jiale and Hu, Xianqing},
  title = {Diagnostic Accuracy of Anti-factor Xa Activity, PT, and APTT for Clinically Relevant Rivaroxaban Levels in Older AF Patients},
  journal = {Clinical and Applied Thrombosis/Hemostasis},
  year = {2026},
  volume = {32},
  doi = {10.1177/10760296261469286}
}
Kostenlos starten →